ReviewFrontiers in genetics2026
Chromatin remodeling and epigenetic regulation of mesenchymal stem/stromal cells in osteoarthritis.
Review in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) creates a persistently hostile joint microenvironment in which inflammatory, mechanical, metabolic, oxidative, and senescence-related cues alter the behavior of mesenchymal stem/stromal cells (MSCs). These changes are not limited to short-term signaling responses, but they should not be interpreted as fixed or irreversible cellular states. Depending on the duration and intensity of environmental exposure, some MSC responses may be transient and reversible, whereas others may be reinforced through epigenetic and chromatin-state regulation, potentially contributing to impaired chondrogenic differentiation, accelerated cellular senescence, and altered paracrine activity, including extracellular vesicles (EVs)-related functions. In this review, we discuss how DNA methylation, histone modifications, long non-coding RNA (lncRNA)-mediated complex recruitment and RNA modifications, chromatin accessibility, and adenosine triphosphate (ATP)-dependent chromatin remodeling connect OA-related stress with OA-associated functional alterations of MSCs. Particular attention is given to the position of chromatin remodeling within the broader epigenetic network. Rather than acting as a separate mechanism, chromatin remodeling provides a structural layer through which regulatory marks, enhancer activity, nucleosome positioning, and transcription-factor access are translated into transcriptional outcomes. We also distinguish different levels of evidence. Data linking epigenetic regulation to MSC chondrogenesis are relatively strong, whereas direct evidence that specific chromatin events determine cargo loading into EVs remains limited. Chromatin regulators such as histone deacetylases (HDACs), BRG1/SMARCA4, and SMARCA5 may serve as mechanistic entry points, but findings from chondrocytes or general MSC models should not be directly extrapolated to OA-derived MSCs without further validation. Finally, we discuss rejuvenation of MSCs, epigenetic preconditioning, microenvironmental engineering, and optimization of EVs as potential strategies for OA regenerative therapy, while emphasizing product heterogeneity, potency testing, patient stratification, and long-term safety as major barriers to translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.